Clinical Trials on Electrophilic Fatty Acids in South Africa

Total 180 results

Altimmune, Inc.

Completed

ALT-801 DDI Study in Healthy Volunteers

NASH - Nonalcoholic Steatohepatitis

Australia
Foundation for Professional Development (Pty) Ltd
National Institute of Allergy and Infectious Diseases (NIAID); University of... and other collaborators

Recruiting

Clinical Study of STI Screening to Prevent Adverse Birth and New-born Outcomes

HIV/AIDS | Pregnancy | Cost-effectiveness | Antenatal Care | Chlamydia Trachomatis | Vaginal Microbiome | Birth Outcomes | Sexually Transmitted Infection | Neisseria Gonorrhoeae | Trichomonas Vaginalis

South Africa
Wake Forest University Health Sciences
National Institute of Mental Health (NIMH)

Not yet recruiting

Adolescents Living With HIV (ALWH): Social Networks, Adherence and Retention

HIV/AIDS

United States, South Africa
Blade Therapeutics

Completed

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BLD-0409 in Healthy Subjects

NASH - Nonalcoholic Steatohepatitis | Chronic Liver Disease

Australia
Pfizer

Completed

2-Week Study In People With Nonalcoholic Fatty Liver Disease

Non-alcoholic Fatty Liver Disease | Non-alcoholic Steatohepatitis

United States
Columbia University
Centers for Disease Control and Prevention

Completed

Pediatric Enhanced Surveillance Study (PESS)

Human Immunodeficiency Virus (HIV) | Acquired Immune Deficiency Syndrome (AIDS)

South Africa
Sheffield Teaching Hospitals NHS Foundation Trust
Bayer

Completed

Testosterone Replacement in Non-alcoholic Steatohepatitis (TEREPINS) (TEREPINS)

Hypogonadism | Nonalcoholic Steatohepatitis

United Kingdom
Centre for Health Systems Research & Development...
World Bank; Bank-Netherlands Partnership Programme (BNPP)

Unknown

Effective Aids Treatment and Support in the Free State (FEATS) (FEATS)

HIV Infections | HIV/AIDS | Food Insecurity

South Africa
Poxel SA

Completed

A Study of the Efficacy and Safety of PXL770 Versus Placebo After 12 Weeks of Treatment in Patients With NAFLD

Nonalcoholic Fatty Liver

United States
Sangart

Completed

Phase IIa Study of MP4OX in Traumatic Hemorrhagic Shock Patients

Shock, Hemorrhagic | Acidosis, Lactic | Shock, Traumatic

France, United Kingdom, South Africa, Germany
Sagimet Biosciences Inc.

Completed

Study of TVB-2640 in Subjects With Nonalcoholic Steatohepatitis (NASH)

Nonalcoholic Fatty Liver Disease

United States, Canada, Puerto Rico, Poland
Pfizer

Completed

6-week Safety and PD Study in Adults With NAFLD

Non-alcoholic Fatty Liver Disease

United States
Akero Therapeutics, Inc

Recruiting

A Study Evaluating Efruxifermin in Subjects With Non-invasively Diagnosed Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Nonalcoholic Fatty Liver Disease (NAFLD)/Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

NASH/MASH | NAFLD/MASLD

United States, Canada, Puerto Rico, Australia, India
NGM Biopharmaceuticals, Inc
NGM Biopharmaceuticals Australia Pty Ltd

Completed

Study of NGM282 in Patients With Nonalcoholic Steatohepatitis (NASH)

Nonalcoholic Steatohepatitis (NASH)

United States, Australia, Puerto Rico
Pfizer

Completed

A Study To Assess Pharmacodynamics, Safety And Tolerability Of PF-05221304 And PF-06865571 Co-Administered For 6 Weeks In Adults With Non-Alcoholic Fatty Liver Disease.

Non-Alcoholic Fatty Liver Disease (NAFLD)

United States
89bio, Inc.
ProSciento, Inc.

Completed

A Multiple Ascending Dose Study of Pegozafermin in Participants With Biopsy Confirmed Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) and at High Risk of NASH

NASH

United States, Puerto Rico
Enyo Pharma

Completed

Safety, Tolerability, Pharmacokinetics and Efficacy of EYP001a in Patients With Nonalcoholic Steatohepatitis (NASH)

Non-alcoholic Steatohepatitis

United States, Belgium, France, Puerto Rico, United Kingdom
AIDS Malignancy Consortium
National Cancer Institute (NCI); University of California, Los Angeles; Merck... and other collaborators

Active, not recruiting

HPV Vaccine Therapy in Reducing High-Grade Cervical Lesions in Patients With HIV and HPV (COVENANT)

HIV Infection | AIDS-Related Human Papillomavirus Infection | High Grade Cervical Squamous Intraepithelial Neoplasia

Uganda, Kenya, Zimbabwe, South Africa, Malawi
Merck Sharp & Dohme LLC

Completed

A Study of Efinopegdutide (MK-6024) in Participants With Nonalcoholic Fatty Liver Disease (NAFLD) (MK-6024-001)

Nonalcoholic Fatty Liver Disease | Nonalcoholic Steatohepatitis

United States, Argentina, Australia, Canada, France, Israel, Italy, Korea, Republic of, Mexico, New Zealand, Poland, Russian Federation, Spain, Taiwan, Turkey, Ukraine
Pfizer

Completed

Phase 2a, Dose-ranging Study With PF-05221304 in Nonalcoholic Fatty Liver Disease (NAFLD)

Nonalcoholic Fatty Liver Disease | Nonalcoholic Steatohepatitis

United States, Israel, Taiwan, Canada, Australia, Poland
Novartis Pharmaceuticals

Terminated

Study of Various Treatments in Non-alcoholic Fatty Liver Disease (NAFLD) Patients Who Have Aspects of Non-alcoholic Steatohepatitis (NASH) (NEXSCOT)

Non-alcoholic Fatty Liver Disease | Nonalcoholic Steatohepatitis

United States, Germany, Argentina
Intercept Pharmaceuticals

Completed

Combination Obeticholic Acid (OCA) and Statins for Monitoring of Lipids (CONTROL) (CONTROL)

Nonalcoholic Steatohepatitis

United States
GlaxoSmithKline

Recruiting

Phase 2b Study of GSK4532990 in Adults With NASH (HORIZON)

Nonalcoholic Fatty Liver Disease

United States, Australia, Italy, Japan, Spain, Belgium, Argentina, Canada, United Kingdom, Korea, Republic of, France, Greece, India, Mexico, Puerto Rico, Turkey, Panama
Altimmune, Inc.

Recruiting

Efficacy and Safety of Pemvidutide in Subjects With Nonalcoholic Steatohepatitis (NASH) (IMPACT Trial) (IMPACT)

Non-Alcoholic Steatohepatitis (NASH)

Australia, United States, Puerto Rico
Target PharmaSolutions, Inc.

Recruiting

A Longitudinal Observational Study of Patients With Nonalcoholic Steatohepatitis (NASH) and Related Conditions Across the Entire Spectrum of Nonalcoholic Fatty Liver Disease (NAFLD)

Nonalcoholic Steatohepatitis | Nonalcoholic Fatty Liver

United States, Germany, Spain
Madrigal Pharmaceuticals, Inc.

Unknown

Phase 2 Study of MGL-3196 in Patients With Non-Alcoholic Steatohepatitis (NASH)

Non-alcoholic Steatohepatitis

United States
Akero Therapeutics, Inc

Active, not recruiting

A Study of Efruxifermin in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) (Symmetry)

NASH - Nonalcoholic Steatohepatitis

United States, Mexico, Puerto Rico
Poxel SA

Completed

Study of PXL065 in Patients With Nonalcoholic Steatohepatitis (NASH)

NASH - Nonalcoholic Steatohepatitis

United States
Immuron Ltd.

Completed

A Phase ll Study of IMM-124E for Patients With Non-alcoholic Steatohepatitis

Non-alcoholic Steatohepatitis (NASH)

United States, Australia, Israel
Novo Nordisk A/S

Recruiting

Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH) (ESSENCE)

Non-alcoholic Steatohepatitis

United States, Korea, Republic of, Australia, Taiwan, Italy, Israel, Canada, Netherlands, Czechia, Malaysia, Spain, Denmark, China, United Kingdom, Singapore, Japan, Puerto Rico, Portugal, Switzerland, Ireland, Belgium, Romania, Ger... and more
Gilead Sciences
Novo Nordisk A/S

Active, not recruiting

Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) (WAYFIND)

Nonalcoholic Steatohepatitis

United States, Spain, Australia, France, Japan, Puerto Rico, Canada
Perspectum
King's College Hospital NHS Trust; University of Coimbra; Liverpool University... and other collaborators

Completed

Non-invasive Rapid Assessment of NAFLD Using Magnetic Resonance Imaging With LiverMultiScan (RADIcAL1)

Metabolic Syndrome | NAFLD | NASH - Nonalcoholic Steatohepatitis

United Kingdom, Germany, Netherlands, Portugal
Akcea Therapeutics
Ionis Pharmaceuticals, Inc.

Completed

Study of ISIS 703802 in Participants With Hypertriglyceridemia, Type 2 Diabetes Mellitus, and Nonalcoholic Fatty Liver Disease

Diabetes Mellitus, Type 2 | NAFLD | Hypertriglyceridemia | Fatty Liver, Nonalcoholic

United States, Canada
Novo Nordisk A/S

Completed

A Research Study on How Semaglutide Works in People With Fatty Liver Disease and Liver Damage

Non-alcoholic Steatohepatitis

United Kingdom, Spain, United States, France, Germany
Novartis Pharmaceuticals

Terminated

Safety, Tolerability, Pharmacokinetics and Efficacy of LMB763 in Patients With NASH

Non-alcoholic Steatohepatitis NASH

United Kingdom, United States, Australia, New Zealand, Switzerland, Jordan, Georgia, Puerto Rico
Novo Nordisk A/S

Active, not recruiting

Research Study on Whether a Combination of 2 Medicines (NNC0194 0499 and Semaglutide) Works in People With Non-alcoholic Steatohepatitis (NASH)

Non-alcoholic Steatohepatitis

Spain, Denmark, Taiwan, Korea, Republic of, Australia, Canada, India, Singapore, United States, Turkey, Poland, Italy, Belgium, Puerto Rico, United Kingdom, Malaysia, Germany, Portugal, Bulgaria, Czechia, France, Greece, Japan, Russian...
Novartis Pharmaceuticals

Terminated

Efficacy, Safety and Tolerability of the Combination of Tropifexor & Licogliflozin and Each Monotherapy, Compared With Placebo in Adult Patients With NASH and Liver Fibrosis. (ELIVATE)

Non Alcoholic Steatohepatitis (NASH)

United States, South Africa, Spain, Germany, Italy, Taiwan, Canada, Korea, Republic of, Singapore, Bulgaria, Estonia, Mexico, Japan, Denmark, United Kingdom, Colombia, Brazil, Belgium, Russian Federation, Puerto Rico, Chile, Argen... and more
Gilead Sciences

Completed

Study to Evaluate the Safety and Efficacy of Selonsertib, Firsocostat, Cilofexor, and Combinations in Participants With Bridging Fibrosis or Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) (ATLAS)

Nonalcoholic Steatohepatitis

Hong Kong, United States, Australia, Puerto Rico, New Zealand, Canada
Akero Therapeutics, Inc

Active, not recruiting

A Study of Efruxifermin in Non-Cirrhotic Subjects With Histologically Confirmed Nonalcoholic Steatohepatitis (NASH) (Harmony)

NASH - Nonalcoholic Steatohepatitis

United States, Puerto Rico
NGM Biopharmaceuticals, Inc

Completed

Study of Aldafermin (NGM282) in Subjects With Compensated Cirrhosis (ALPINE 4)

Nonalcoholic Steatohepatitis | Compensated Cirrhosis

United States, Australia, Belgium, France, Germany, Hong Kong, Poland, Puerto Rico, United Kingdom
89bio, Inc.

Active, not recruiting

Study Evaluating the Safety, Efficacy and Tolerability of BIO89-100 in Subjects With Biopsy-confirmed Nonalcoholic Steatohepatitis (NASH) (ENLIVEN)

NASH - Nonalcoholic Steatohepatitis

United States, Puerto Rico
Merck Sharp & Dohme LLC

Terminated

A Study of MK-3655 in Individuals With Pre-cirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-3655-001)

Nonalcoholic Steatohepatitis

Korea, Republic of, United States, Argentina, Australia, Canada, Chile, China, Colombia, France, Germany, Greece, Hong Kong, Israel, Italy, Japan, Malaysia, Mexico, New Zealand, Puerto Rico, Russian Federation, Spain, Sweden, Taiwan, ...
Sanofi

Terminated

An Efficacy and Safety Study of Rimonabant for Treatment of Nonalcoholic Steatohepatitis (NASH) in Patients Without Diabetes

Fatty Liver

United States, France, Brazil, Poland, Romania, Germany, Portugal, Spain, Switzerland, Malaysia, Philippines, Taiwan, Belgium, Mexico, Argentina, Croatia, Hungary, Italy, Colombia, Chile, United Kingdom, Puerto Rico, Australia, China
Sanofi

Terminated

An Efficacy and Safety Study of Rimonabant for Treatment of Nonalcoholic Steatohepatitis (NASH) in Patients With Type 2 Diabetes

Fatty Liver

United States, France, Brazil, Poland, Romania, Germany, Portugal, Spain, Switzerland, Malaysia, Philippines, Taiwan, Belgium, Mexico, Argentina, Croatia, Hungary, Italy, Colombia, Chile, United Kingdom, Puerto Rico, Australia, China
Gilead Sciences

Terminated

Safety and Efficacy of Selonsertib in Adults With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) (STELLAR-4)

Nonalcoholic Steatohepatitis

United States, Spain, Hong Kong, Canada, Belgium, Australia, Taiwan, India, Japan, Korea, Republic of, Singapore, United Kingdom, Israel, Puerto Rico, France, New Zealand, Germany, Austria, Italy, Mexico, Poland, Switzerland
Viking Therapeutics, Inc.

Active, not recruiting

A Study to Assess the Efficacy and Safety of VK2809 for 52 Weeks in Subjects With Biopsy Proven NASH (VOYAGE)

NASH - Nonalcoholic Steatohepatitis

United States, Belgium, France, Mexico, Puerto Rico
Duke University
National Institute on Minority Health and Health Disparities (NIMHD)

Completed

Pathways to Cardiovascular Disease Prevention (DCRI Central and Statistical Coordinating Center)

Cardiovascular Diseases | HIV/AIDS

United States
Gilead Sciences

Terminated

Two Part Study to Evaluate Pharmacokinetics, Safety, and Antiviral Activity of Elvitegravir Administered With a PI/r Background Regimen for ARV Treatment-Experienced Pediatric Participants

HIV Infections | Acquired Immune Deficiency Syndrome (AIDS)

United States, Thailand, Spain, Uganda, South Africa, Italy
Intercept Pharmaceuticals

Completed

Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (REVERSE)

Nonalcoholic Steatohepatitis | Compensated Cirrhosis

United States, Spain, France, Australia, New Zealand, Puerto Rico, Germany, Canada, United Kingdom, Hungary, Poland, Ukraine
Akero Therapeutics, Inc

Recruiting

A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis

NASH With Fibrosis | MASH With Fibrosis

United States, Canada, Puerto Rico, Australia, India, France, Italy, Poland, Spain

Clinical Trials on Electrophilic Fatty Acids in South Africa

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Poland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations